Article
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
Blood advances - 28 Mar 2023
Issa Ghayas C, Bidikian Aram, Venugopal Sangeetha, Konopleva Marina, DiNardo Courtney D, Kadia Tapan M, Borthakur Gautam, Jabbour Elias, Pemmaraju Naveen, Yilmaz Musa, Short Nicholas J, Maiti Abhishek, Sasaki Koji, Masarova Lucia, Pierce Sherry, Takahashi Koichi, Tang Guilin, Loghavi Sanam, Patel Keyur, Andreeff Michael, Bhalla Kapil, Garcia-Manero Guillermo, Ravandi Farhad, Kantarjian Hagop, Daver Naval
Abstract excerpt
Mutations in Nucleophosmin 1 (NPM1) are associated with a favorable prognosis in newly diagnosed acute myeloid leukemia (AML), however, their prognostic impact in relapsed/refractory (R/R) settings are unknown. In a retrospective analysis, we identified 206 patients (12%) with mutated NPM1 (NPM1c) and compared their outcomes to 1516 patients (88%) with NPM1 wild-type (NPM1wt). NPM1c was associated with higher...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.